# **YIRU WANG**

Partner Fangda Partners

+86 21 2208 1107 yiru.wang@fangdalaw.com



#### **PRACTICE AREAS**

MR. WANG SPECIALIZES IN PRIVATE EQUITY, CROSS -BORDER RESTRUCTURING, MERGER AND ACQUISITION.

# **REPRESENTATIVE MATTERS AND CASES**

Private Equity and Cross-Border Restructuring

- Represented Ant Financial in its investment in Hellobike, the operator of the largest bike-sharing platform in China, and relevant cross-border restructuring of Hellobike
- Represented Ant Financial in its investment in a strategic joint venture with Hellobike and CATL
- Represented Warburg Pincus in the cross-border restructuring and subsequent listing on NEEQ of Kidswant, a leading maternity-infant-children specialty retailer
- Represented Warburg Pincus in the cross-border restructuring and subsequent IPO of Liepin, the largest mid-senior level professional & talent online platform in China
- Represented Goldman Sachs in the cross-border restructuring and subsequent IPO of Ascletis Pharma, a leading biotechnology company
- Represented Alibaba in its investment in AISpeech, a leading speech technology platform
- Represented Alibaba and YF Capital in its investment in Qiniu Cloud, a leading enterprise cloud service supplier
- Represented YF Capital in its investment in Montage Tech, a leading provider of analog and mixed-signal semiconductor solutions

- Represented YF Capital in its investment in Leyan Tech, a leading artificial intelligence customer service provider
- Represented Hillhouse in its investment in Gaodun, a leading online professional education service provider
- Represented ANE Logstics, a leading trucking and logistics services provider, in its share structure restructuring and equity financing
- Represented Pipilu, a leading children entertainment content and products provider, in its cross-border restructuring and equity financing
- Represented MitrAssist, an Isreali medical device manufacturer, in its share structure restructuring and equity financing
- Represented CstonePharma, a biopharma company focused on developing innovative immuno-oncology and molecularly targeted drugs, in its pre-IPO restructuring
- Represented WukongZhaoFang, Panda ABC, Eddingpharm in their equity financings

Merger and Acquisition

- Represented City Development Limited in its RMB 4.4 billion acquisition of equity in Chongqing Sincere
- Represented Eddingpharm in its US\$375 million acquisition of certain onshore business of Lilly
- Represented Fujian Automobile Group Limited on the RMB 690 million acquisition of 35% equity in Fujian Benz Automotive Co., Ltd. (a Sino-foreign joint venture) by BAIC Motor Corporation Limited (01958.HK)
- Represented Morgan Stanley on the RMB800 million acquisition of 11% equity in Hangzhou Trust by Greenland Holdings Group Corporation Limited (600606)
- Represented Warburg Pincus in its acquisition of equity in a company engaged in education business
- Represented Vastec Medical Limited on the US\$60 million takeover by Shinva Medical Instrument Co., Ltd. (600587)
- Represented Suzhou Anjie Technology Co., Ltd. (002635) on its US\$145 million takeover of Supernova Holdings (Singapore) Pte. Ltd.

### OTHER INFORMATION

### Education

- New York University, School of Law, LLM
- East China University of Political Science and Law, LLB

#### **Professional Qualification**

- Admitted to practice in the PRC
- Admitted to practice in New York

## **Professional Background**

Mr. Wang joined Fangda Partners in 2015. Prior to joining Fangda Partners, he worked with a leading Chinese domestic law firm.